source
- Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trialServier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…
- Scientists question safety and benefits of three-parent IVF as new UK data raise concernsThe mitochondrial replacement technique, often called three‑parent IVF, was hailed after the United Kingdom reported the birth of eight healthy children whose mothers carried disease‑causing mitoch…